NCI Launches Molecular Medicine Clinical Trials; Response Genetics Nabs Profiling Contract | GenomeWeb

NEW YORK (GenomeWeb) – The National Cancer Institute said today it has launched new clinical trials that will use tumor sequencing and genetic markers to help determine whether therapies targeting genetic alterations can prevent lung cancer recurrence.

Separately, Response Genetics said it has been awarded a "multi-million dollar" subcontract from Leidos Biomedical Research, a contractor for the NCI-sponsored Frederick National Laboratory for Cancer Research, to handle molecular profiling for the trials. Further details about the subcontract's terms were not immediately available.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."